Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 329

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus

Ostendorf, Lennard, Burns, Marie, Durek, Pawel, Heinz, Gitta Anne, Heinrich, Frederik, Garantziotis, Panagiotis, Enghard, Philipp, Richter, Ulrich, Biesen, Robert, Schneider, Udo, Knebel, Fabian, Burmester, Gerd, Radbruch, Andreas, Mei, Henrik E., Mashreghi, Mir-Farzin, Hiepe, Falk, Alexander, Tobias·2020·New England Journal of Medicine

Abstract

Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies, but they are unresponsive to standard immunosuppression. We describe the use of daratumumab that induced substantial clinical responses in two patients with life-threatening lupus, with the clinical responses sustained by maintenance therapy with belimumab, an antibody to B-cell activating factor. Significant depletion of long-lived plasma cells, reduction of interferon type I activity, and down-regulation of T-cell transcripts associated with chronic inflammation were documented. (Supported by the Deutsche Forschungsgemeinschaft and others.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2023325

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 329

Metadata

Authors
Ostendorf, L., Burns, M., Durek, P., Heinz, G. A., Heinrich, F., Garantziotis, P., Enghard, P., Richter, U., Biesen, R., Schneider, U., Knebel, F., Burmester, G., Radbruch, A., Mei, H. E., Mashreghi, M.-F., Hiepe, F., & Alexander, T.
Venue
New England Journal of Medicine
Published
2020-09-17
Volume
383
Issue
12
Pages
1149-1155
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3086471819
Cited by
329
References
21
FWCI
27.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. https://app.cochat.ai/papers/10.1056/nejmoa2023325
The paper
Ostendorf, L., Burns, M., Durek, P., Heinz, G. A., Heinrich, F., Garantziotis, P., Enghard, P., Richter, U., Biesen, R., Schneider, U., Knebel, F., Burmester, G., Radbruch, A., Mei, H. E., Mashreghi, M.-F., Hiepe, F., & Alexander, T. (2020). Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2023325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.